Reuters: Regulatory News: UPDATE 1-Use of new Boston Scientific device should be limited - doctor

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-Use of new Boston Scientific device should be limited - doctor Jan 2nd 2013, 20:55 Wed Jan 2, 2013 3:55pm EST By Debra Sherman CHICAGO Jan 2 (Reuters) - Boston Scientific Corp's new leadless implantable heart defibrillator, hailed by some as a breakthrough, should be used on a limited basis until more data are collected, a prominent cardiologist wrote in an editorial of a top medical journal. Leads, or wires that carry electrical pulses from the defibrillator - which is implanted in the chest - to the heart have always been the weak link in these systems, used to treat irregular heart beats. All of the device makers have had problems at one time or another with leads. Boston Scientific bought the leadless technology, known as a subcutaneous implantable cardioverter-defibrillator, or S-ICD, when it acquired Cameron Health last year. The Cameron device was approved by the U.S. Food and Drug Administration in the fourth quarter. "The S-ICD has not yet been shown to be safe and effective in a diverse patient population," Robert Hauser wrote in the January issue of the Journal of the American College of Cardiology. Hauser, of the Minneapolis Heart Institute, who has been a vocal critic of medical device companies, also noted that the leadless ICD has not even been shown to be as good as the traditional ICDs that use leads. He said the technology is a promising one that could fill important gaps, especially by bringing it to countries where facilities to implant traditional devices is not available, but more data are needed first. "Unless critical questions with regard to safety and efficacy in primary and secondary prevention are addressed, the S-ICD should be confined to certain subgroups," he said. Dr. Ken Stein, Boston Scientific's Chief Medical Officer for Cardiac Rhythm Management, said there was more in Hauser's editorial that he agreed with than disagreed with. "But it was approved by the FDA as being safe and effective," he noted in a telephone interview. "It's an alternative for physicians to consider. We agree there are absolutely some patient populations that shouldn't get it," he said. For example, patients who are at high risk of infections should not get it, he said. Patients who have a slow heartbeat or uncoordinated pumping function should not get it because the S-ICD cannot pace a slow heart beat or resynchronize contractions of the heart's ventricles. "For some patient populations, this is the best option," Stein said. "Somewhere in that middle ground is where the line should be drawn." Stein said the company is currently running clinical trials and registers that will render more data, some of which will be presented in the spring at the Heart Rhythm Society meeting. Link this Share this Digg this Email Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions